NICE denies patients with terminal kidney cancer access to Axitinib

Broadcaster James Whale MBE, Chairman of the Kidney Cancer UK and himself a kidney cancer survivor, commented that the National Institute for Health and Clinical Excellence (NICE) decision to not approve Axitinib (Inlyta) as a second line treatment for patients with advanced kidney cancer seems to go against all the evidence that this drug would prolong the life of the patient.  In other parts of Europe it is a doctor that decides the patient’s treatment not a disassociated committee.

The Fund considers the decision to refuse the drug as unacceptable, and will continue to lobby NICE and members of Parliament to have this ludicrous decision overturned.